.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Novartis
Moodys
Citi
US Army
Baxter
US Department of Justice
Cerilliant
Daiichi Sankyo
Cipla

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202102

« Back to Dashboard
NDA 202102 describes ARIPIPRAZOLE, which is a drug marketed by Alembic Pharms Ltd, Amneal Pharms, Teva Pharms Usa, Aurobindo Pharma Ltd, Macleods Pharms Ltd, Torrent Pharms Ltd, Accord Hlthcare, Hetero Labs Ltd V, Silarx Pharms Inc, Ajanta Pharma Ltd, Santos Biotech, Apotex Inc, Orchid Hlthcare, and Sciegen Pharms Inc, and is included in nineteen NDAs. It is available from twenty-nine suppliers. Additional details are available on the ARIPIPRAZOLE profile page.

The generic ingredient in ARIPIPRAZOLE is aripiprazole. There are forty-four drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

Summary for NDA: 202102

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202102

Suppliers and Packaging for NDA: 202102

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARIPIPRAZOLE
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL 202102 ANDA Trigen Laboratories, LLC 13811-692 13811-692-30 30 TABLET, ORALLY DISINTEGRATING in 1 CARTON (13811-692-30)
ARIPIPRAZOLE
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL 202102 ANDA Trigen Laboratories, LLC 13811-693 13811-693-30 30 TABLET, ORALLY DISINTEGRATING in 1 CARTON (13811-693-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength10MG
Approval Date:Apr 28, 2015TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength15MG
Approval Date:Apr 28, 2015TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Argus Health
Healthtrust
Mallinckrodt
Merck
Citi
Farmers Insurance
QuintilesIMS
Dow
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot